Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

A cancer, female technology, used in disease diagnosis, biological testing, measurement devices, etc., to solve problems such as undescribed correlations

Active Publication Date: 2013-09-18
SPHINGOTEC
View PDF19 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the same authors note that no clear association between circulating neurotensin and the stage of pancreatic, prostate, or medullary thyroid tumors has been described, which may be due to rapid hepatic clearance of neurotensin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
  • A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
  • A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Antibody preparation

[0090] Peptides / Conjugates for Immunization

[0091] Peptides for immunization were synthesized (JPT Technologies, Berlin, Germany) with an additional N-terminal cysteine ​​residue to couple the peptide to bovine serum albumin (BSA). The peptide was covalently coupled to BSA by using Sulfo-SMCC (Perbio-science, Bonn, Germany). Coupling steps were performed according to Perbio's manual.

[0092] Labeled Antibody (LA) Peptides (P-NT 1-19):

[0093] H-CSDSEEEMKALEADFLTNMH-NH2

[0094] Solid Phase Antibody (SPA) Peptide (P-NT 44-62):

[0095] H-CNLNSPAEETGEVHEEELVA-NH2

[0096] Generate antibodies as follows:

[0097] BALB / c mice were immunized with 100 μg of peptide-BSA conjugate on days 0 and 14 (emulsified in 100 μl complete Freund’s adjuvant) and 50 μg on days 21 and 28 (in 100 μl in incomplete Freund's adjuvant). Animals received 50 μg of conjugate dissolved in 100 μl of saline by one intraperitoneal injection and one intravenous inje...

Embodiment 2

[0104] Immunoassay for quantification of human proneurotensin

[0105] The technique used is based on acridinium ester labeled sandwich-coated tube luminescence immunoassay.

[0106] Labeled complex (tracer): 100 μg (100 μl) LA (1 mg / ml dissolved in PBS, pH 7.4) was mixed with 10 μl acridine NHS ester (1 mg / ml dissolved in acetonitrile, InVent GmbH, Germany) (EP 0353971 ) and incubate at room temperature for 20 minutes. Labeled LA was purified by gel filtration HPLC on Bio-Sil SEC 400-5 (Bio-Rad Laboratories, Inc., USA). Purified LA was diluted in (300 mmol / l potassium phosphate, 100 mmol / l NaCl, 10 mmol / l Na-EDTA, 5 g / l bovine serum albumin, pH 7.0). The final concentration was approximately 800.000 relative light units (RLU) of labeled complex (approximately 20 ng of labeled antibody) per 200 μl. Acridine ester chemiluminescence was measured with AutoLumat LB 953 (Berthold Technologies GmbH & Co. KG).

[0107] Solid phase: Polystyrene tubes (Greiner Bio-One Internation...

Embodiment 3

[0116] group study

[0117] method

[0118] We measured P-NT in fasting plasma from 2559 female participants who were included in the baseline examination of the Malmö Diet and Cancer Study in 1991-1994 (mean age 58±6 years, 59 females). %). We compared baseline P-NT (to log-transformed P- Hazard ratio per one standard deviation increase in NT) was associated with time to first event for each study endpoint, with a median follow-up of more than 12 years. Endpoints were retrieved from the Swedish National Hospital Discharge Register, the Swedish Myocardial Infarction Register, the Malmö Stroke Register, and the Swedish Cancer Register. Endpoints retrieved through these registries were validated and found to be accurate (see also Belting et al., Cancer Epidemiol Biomarkers Prev; 1-10._2012 AACR)).

[0119] Clinical characteristics of women in the study

[0120] descriptive statistics

[0121] Table 1

[0122]

[0123] Table 2

[0124] Questionnaire + diary recor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of pro-neurotensin or fragments thereof with the a risk for getting cancer, wherein an elevated level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an elevated level is correlated with the diagnosis of cancer and, wherein said cancer is selected from the group comprising breast cancer, lung cancer, pancreatic cancer and colon cancer.

Description

technical field [0001] A subject of the present invention is a method for predicting the risk of developing cancer in a female subject not suffering from cancer or diagnosing cancer in a female subject, said method comprising: [0002] Determining the level of proneurotensin or a fragment thereof of at least 5 amino acids in a body fluid obtained from said female subject; and [0003] correlating said levels of proneurotensin or fragments thereof with risk of developing cancer, wherein elevated levels are indicative of increased risk of developing cancer, or for diagnosing cancer, wherein elevated levels are correlated with diagnosis of cancer ,and [0004] Wherein said cancer is selected from breast cancer, lung cancer, pancreatic cancer and colon cancer. Background technique [0005] Neurotensin is a 13 amino acid neuropeptide derived from the precursor of preproneurotensin and is released in stoichiometric proportions with the stable 117 amino acid peptide proneurotensi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/574G01N33/57415G01N33/74G01N2333/726G01N2800/50G01N2800/52A61P35/00G01N33/57488
Inventor 安德里斯·贝格曼欧勒·米兰德
Owner SPHINGOTEC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com